Source Citation
Levi M, Levy M, Williams MD, et al. Prophylactic heparin in patients with severe sepsis treated with drotrecogin alfa (activated). Am J Respir Crit Care Med. 2007;176:483-90. https://pubmed.ncbi.nlm.nih.gov/17556722
Clinical Impact Ratings
Hospitalists: 
Hematology: 
Infectious Disease:
Critical Care:
References
- 1 Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001;344:699-709. [PMID: 11236773] Google Scholar
- 2 FDA briefing document: anti-infective advisory committee drotrecogin alfa (activated). www.fda.gov/ohrms/dockets/ac/01/briefing/3797b1_02_FDAbriefing.pdf (accessed on 20 December 2007). Google Scholar
- 3 Zarychanski R, Gulati H, Roberts D, et al. Systemically administered therapeutic dose heparin is associated with increased survival in patients diagnosed with septic shock. Crit Care Med. 2006;34 (suppl):A110, 398. Google Scholar
- 4 Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126:338S-400S. [PMID: 15383478] Google Scholar
Author, Article, and Disclosure Information
Authors:
Deborah Cook,
McMaster University, Hamilton, Ontario, Canada (D.C.)
Submit a Comment
Contributors must reveal any conflict of interest. Comments are moderated. Please see our information for authorsregarding comments on an Annals publication.
*All comments submitted after October 1, 2021 and selected for publication will be published online only.